Related Experiment Video
Updated: Jun 25, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
New European guidelines for cardiovascular disease prevention in clinical practice
1Department of Public Health, Ghent University, Ghent, Belgium. guy.debacker@ugent.be
Insights
The 2007 European guidelines for cardiovascular disease (CVD) prevention emphasize lifestyle changes, risk factor management, and cardioprotective drugs. Clinical chemists should note updates on CVD prevention strategies and their implications.
Area of Science:
- Cardiology
- Clinical Chemistry
- Preventive Medicine
Background:
- The Fourth Joint European Societies' Task Force updated cardiovascular disease (CVD) prevention guidelines in 2007.
- These guidelines are supported by 10 international societies.
Purpose of the Study:
- To summarize the 2007 European guidelines for CVD prevention.
- To highlight new aspects compared to previous guidelines.
- To identify information relevant to clinical chemists.
Main Methods:
- Review and summarization of the 2007 Joint European Societies' Task Force guidelines.
- Focus on updates concerning lifestyle modifications, risk factor control, and pharmacotherapy.
Main Results:
- The updated guidelines provide comprehensive recommendations for CVD prevention.
- Key updates include refined strategies for risk factor management and drug selection.
- Specific considerations for clinical chemists are outlined.
Conclusions:
- The 2007 guidelines offer an updated framework for preventing cardiovascular disease in clinical practice.
- Clinical chemists play a role in implementing and monitoring these preventive strategies.
Abstract:
In 2007, the Fourth Joint European Societies' Task Force on cardiovascular disease (CVD) prevention in clinical practice issued an update of the guidelines on how to prevent CVD. These guidelines are endorsed by 10 international societies interested in the subject. Particular attention is given to lifestyle changes, risk factor management, and the use of cardioprotective drugs. In this paper, the content of the guidelines is summarized with emphasis on what is new compared to the previous version and on what could be of particular interest to clinical chemists. For those who would like to read more on this, please refer to the full document (112 pages including 1105 references).
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease III: Clinical Manifestations
Atherosclerosis III: Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Rheumatic Heart Disease III: Medical Management
